Is ABBV a buy, hold, or sell?
ABBV carries a valuation grade of Strong Buy. The trailing P/E of 105.6 sits 380% above the Healthcare sector median of 22.0x — a premium that demands sustained earnings delivery. Our discounted cash flow model produces an intrinsic range of $223–$417 — implying a +48% margin of safety at the current price of $216.49. The width of the DCF range reflects genuine uncertainty in the terminal growth rate assumption: the correct framework is a probability-weighted distribution over scenarios, not a single point estimate. See the DCF valuation framework for full methodology.
With a 9% beat rate on recent quarters, earnings predictability has been mixed. The most recent quarter missed by a 77.0% earnings surprise. Analyst estimate revisions are trending upward.
What are ABBV's key risk factors?
With a beta of 0.31, ABBV exhibits a low-volatility risk profile relative to the broad market. The 95th-percentile CVaR of -10.3% on a one-month horizon should inform position sizing directly: at a 10% portfolio weight, this tail event contributes approximately 1.0% of total portfolio loss in the worst 5% of months. Net margins of 5.8% fall below the Healthcare sector average of 18%, suggesting margin pressure.
At 0.40, the put/call ratio skews bullish, with call buyers dominating recent flow. Implied volatility of 29.4% exceeds realized volatility of 24.1% by 5 points, suggesting options are pricing in elevated risk. Insiders have been net sellers to the tune of $104.4M recently. While routine dispositions are common, the magnitude bears watching. Short interest is low at 1.5% of float, suggesting limited bearish conviction.
How does ABBV fit in a diversified portfolio?
At typical HENRY portfolio weights — 10–20% of the equity allocation — ABBV carries a beta of 0.31, meaning it amplifies broad market moves proportionally. The appropriate weight is not a function of conviction alone, but of the full covariance structure across all holdings. See the Ledoit-Wolf covariance framework for the methodology behind these calculations.
Among closely correlated names, ABBV shows the strongest co-movement with JNJ (0.43), PFE (0.42), LLY (0.28). Investors seeking diversification should note these correlation dynamics when constructing multi-asset portfolios.
True portfolio risk is a function of the full covariance structure across all holdings — not individual stock metrics. The Portfolio Health Check quantifies this at the portfolio level: it surfaces hidden concentration, marginal CVaR contributions, and the degree to which your overall allocation deviates from an optimal risk-adjusted mandate. The ABBV analysis here is a single node in that larger structure.
For the portfolio construction framework underpinning ABBV’s position sizing and conviction rating — including IPS guardrails, Black-Litterman allocation, and CVaR constraints — see: Investment Policy Statement Framework →
